Concomitant use of direct oral anticoagulants with antiplatelet agents, NSAIDs, or serotonergic agents increases the risk of bleeding and requires routine assessment and skilled management.
-glycoprotein may interact with all direct oral anticoagulants, and modifiers of cytochrome 3A4 may interact with rivaroxaban and apixaban. Antiplatelet agents, nonsteroidal anti-inflammatory drugs, and serotonergic agents, such as selective serotonin reuptake inhibitors, can increase risk of bleeding when combined with any oral anticoagulant, and concomitant use should be routinely assessed. New data on anticoagulant drug interactions are available almost daily, and therefore, it is vital that clinicians regularly search interaction databases and the literature for updated management strategies. Skilled drug interaction management will improve outcomes and prevent adverse events in patients taking oral anticoagulants.
Sara R. Vazquez (Wed,) conducted a review in Patients taking oral anticoagulants. Direct oral anticoagulants was evaluated. Concomitant use of direct oral anticoagulants with antiplatelet agents, NSAIDs, or serotonergic agents increases the risk of bleeding and requires routine assessment and skilled management.